WIRED News Names Cyberkinetics' BrainGate(TM) System as One of
''Biggest Discoveries of 2005''
FOXBOROUGH, Mass.--(BUSINESS WIRE)--Jan. 9, 2006--WIRED News
(www.wired.com) ranked Cyberkinetics' (Cyberkinetics Neurotechnology
Systems, Inc.; OTCBB: CYKN; "Cyberkinetics") BrainGate(TM) Neural
Interface System ("BrainGate System") as one of the top five
scientific and technical discoveries in its "Biggest Discoveries of
2005." A complete list of the discoveries and rankings is available at
(http://www.wired.com/news/technology/0,69909-0.html).


Ranking the BrainGate System as one of WIRED's top five scientific and
technical discoveries, author Leander Kahney cited Matthew Nagle,
first participant in Cyberkinetics' pilot clinical trial of the
BrainGate System, as the "first neuro-cybernaut...the first paralyzed
person to control an artificial hand by brain power alone." Using the
BrainGate System, Nagle also demonstrated his ability to control light
switches, open his e-mail, play video games, operate a computer and
change channels on his television.

With its proprietary FDA 510K-approved NeuroPort(TM) Neural Monitoring
product scheduled for launch in 2006 and its award-winning BrainGate
System the subject of two pilot clinical trials, Cyberkinetics is a
recognized leader in the emerging neurotechnology industry. Currently,
industry analysts estimate that worldwide neurotechnology device
industry revenue exceeds $2 billion annually. Those analysts expect
that neurotechnology-related revenues will approach $5 billion in the
next five years - spotlighting the industry as one of the
fastest-growing markets for medical technology today.

About the BrainGate(TM) System

The BrainGate Neural Interface System is Cyberkinetics' proprietary,
investigational brain-computer interface (BCI) that consists of an
internal sensor to detect brain cell activity and external processors
that convert these brain signals into a computer-mediated output under
the person's own control. The sensor is a tiny silicon chip about the
size of a baby aspirin with one hundred electrodes, each thinner than
a human hair, that can detect the electrical activity of neurons. The
sensor is implanted on the surface of the area of the brain
responsible for movement, the motor cortex. The ultimate goal of the
BrainGate System development program is to create a safe, effective
and unobtrusive universal operating system that could enable those
with severe motor impairments resulting from a variety of causes to
quickly and reliably control a wide range of devices, including
computers, assistive technologies and medical devices, simply by using
their thoughts.

A pilot study of the BrainGate System is currently underway in those
with severe paralysis resulting from spinal cord injury (SCI),
muscular dystrophy, or with "locked-in" syndrome (tetraplegia and the
inability to speak) secondary to stroke. Enrollment for the BrainGate
SCI study is currently open through the Spaulding Rehabilitation
Hospital in Boston, Massachusetts, the Rehabilitation Institute of
Chicago in Illinois, and the Sargent Rehabilitation Center in
Providence, Rhode Island.

A second pilot study is currently enrolling individuals with ALS
(Amyotrophic Lateral Sclerosis or Lou Gehrig's disease) or another
motor neuron disease (MND) at the Massachusetts General Hospital in
Boston, Massachusetts. A long-term goal of this research is to develop
a system that can be used by those with ALS or other motor neuron
diseases without the assistance of a technician.

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, a leader in brain interface
technology, is developing products to treat nervous system diseases
and disorders by bringing together advances in neuroscience, computer
science and engineering. Cyberkinetics' products are based on over ten
years of technology development and cutting-edge neuroscience research
at Brown University, the Massachusetts Institute of Technology, Emory
University, and the University of Utah.

Cyberkinetics has received FDA clearance to market the NeuroPort
System, a neural monitor designed for acute inpatient applications and
labeled for temporary (less than 30 days) recording and monitoring of
brain electrical activity. The NeuroPort System can contribute to the
diagnosis and treatment of neurological conditions in patients who
have undergone a craniotomy by providing neurologists and
neurosurgeons a new resource to detect, transmit and analyze neural
activity.

Cyberkinetics' BrainGate System is being designed to give severely
paralyzed individuals, as well as individuals with motor impairment
from a variety of causes, a long-term, direct brain-computer interface
for the purpose of communication and control of a computer, assistive
devices, and, ultimately, limb movement.

Additional information about Cyberkinetics is available on the
Company's website at www.cyberkineticsinc.com. For specific
information about BrainGate clinical trials please send an email to
braingateinfo@cktrial.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including
statements about Cyberkinetics' product development plans and
progress. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
and can be identified by the use of forward-looking terminology such
as "may," "will," "believe," "expect," "anticipate" or other
comparable terminology. Forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from those projected in forward-looking statements and reported
results shall not be considered an indication of our future
performance. Factors that might cause or contribute to such
differences include our limited operating history; our lack of profits
from operations; our ability to successfully develop and commercialize
our proposed products; a lengthy approval process and the uncertainty
of FDA and other governmental regulatory requirements; clinical trials
may fail to demonstrate the safety and effectiveness of our products;
the degree and nature of our competition; our ability to employ and
retain qualified employees; compliance with recent legislation
regarding corporate governance, including the Sarbanes-Oxley Act of
2002; as well as those risks more fully discussed in our public
filings with the Securities and Exchange Commission, all of which are
difficult to predict and some of which are beyond our control.